The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Spectrum Pharmaceuticals Inc

Nasdaq: SPPI
Last

(U.S.) $6.44

Today's change-0.18 -2.72%
Updated September 3 1:24 PM EDT. Delayed by at least 15 minutes.
 

Spectrum Pharmaceuticals Inc

Nasdaq: SPPI
Last

(U.S.) $6.44

Today's change-0.18 -2.72%
Updated September 3 1:24 PM EDT. Delayed by at least 15 minutes.

Spectrum Pharmaceuticals Inc crosses below 125-day moving average

Spectrum Pharmaceuticals Inc is sharply lower today, dropping (U.S.)$0.18 or 2.72% to (U.S.)$6.44 and crossing below its 125-day moving average. Over the last five days, shares have lost 14.02% and are down 7.07% for the last year to date. This security has underperformed the S&P 500 by 17.59% during the last year.

Key company metrics

  • Open(U.S.) $6.65
  • Previous close(U.S.) $6.62
  • High(U.S.) $6.82
  • Low(U.S.) $6.34
  • Bid / Ask(U.S.) $6.43 / (U.S.) $6.44
  • YTD % change-7.07%
  • Volume1,468,675
  • Average volume (10-day)1,999,595
  • Average volume (1-month)1,657,076
  • Average volume (3-month)1,025,796
  • 52-week range(U.S.) $5.45 to (U.S.) $8.50
  • Beta1.59
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.65
Updated September 3 1:24 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-23.12%

Although this company's net profit margin is negative, it is above the industry average and implies that Spectrum Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.33%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue45395248
Total other revenue--------
Total revenue45395248
Gross profit39324441
Total cost of revenue6787
Total operating expense45605352
Selling / general / administrative23232424
Research & development10161414
Depreciation / amortization71477
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income0-22-2-4
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-2-25-3-8
Income after tax-2-26-3-12
Income tax, total0003
Net income-2-26-3-12
Total adjustments to net income--------
Net income before extra. items-2-26-3-12
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-2-26-3-12
Inc. avail. to common incl. extra. items-2-26-3-12
Diluted net income-2-26-3-12
Dilution adjustment------0
Diluted weighted average shares65656665
Diluted EPS excluding extraordinary itemsvalue per share-0.04-0.39-0.05-0.18
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.04-0.39-0.05-0.18